Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported EBITDA Margin over the past 9 years, most recently at 1998.77% for Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 1998.77%; the TTM value through Dec 2025 reached 6034.5%, up 2268754.0%, while the annual FY2025 figure was 6034.5%, 2268754.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 1998.77% at Crinetics Pharmaceuticals, up from 90572.03% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1163.75% in Q1 2022 and troughed at 90572.03% in Q3 2025.
  • A 5-year average of 15168.89% and a median of 9717.66% in 2022 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 739241bps in 2025 and fell as far as -1593236bps in 2025.
  • Year by year, EBITDA Margin stood at 2890.91% in 2021, then tumbled by -114bps to 6193.51% in 2022, then crashed by -164bps to 16363.58% in 2023, then fell by -14bps to 18645.36% in 2024, then skyrocketed by 89bps to 1998.77% in 2025.
  • Business Quant data shows EBITDA Margin for CRNX at 1998.77% in Q4 2025, 90572.03% in Q3 2025, and 11252.96% in Q2 2025.